Elanco Animal Health Files 8-K on Operations and Exit Costs

Ticker: ELAN · Form: 8-K · Filed: 2024-02-26T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, operational-update, restructuring

TL;DR

**Elanco just dropped an 8-K detailing their latest financial results and some exit costs, so keep an eye on their operational efficiency!**

AI Summary

Elanco Animal Health Inc. filed an 8-K on February 22, 2024, reporting on its results of operations and financial condition, as well as costs associated with exit or disposal activities. The filing indicates the company's current financial status and any significant restructuring costs incurred.

Why It Matters

This filing provides investors with crucial insights into Elanco's recent financial performance and any strategic changes involving asset disposals or operational exits, which can impact future profitability.

Risk Assessment

Risk Level: medium — The filing is an informational update without immediate indication of significant positive or negative financial events.

Key Players & Entities

FAQ

What was the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing was February 22, 2024.

What items of information were included in this 8-K filing?

The 8-K filing included information on Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, and Financial Statements and Exhibits.

What is the Registrant's telephone number?

The Registrant's telephone number is (877) 352-6261.

What is the Commission File Number for Elanco Animal Health Inc.?

The Commission File Number for Elanco Animal Health Inc. is 001-38661.

Where is Elanco Animal Health Inc.'s principal executive office located?

Elanco Animal Health Inc.'s principal executive office is located at 2500 INNOVATION WAY, GREENFIELD, INDIANA, 46140.

From the Filing

0001739104-24-000004.txt : 20240226 0001739104-24-000004.hdr.sgml : 20240226 20240226063015 ACCESSION NUMBER: 0001739104-24-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240222 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240226 DATE AS OF CHANGE: 20240226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 24673487 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 elan-20240222.htm 8-K DATED FEBRUARY 22, 2024 elan-20240222 FALSE 0001739104 0001739104 2024-02-22 2024-02-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ Form 8-K _______________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Elanco Animal Health Inc orporated (Exact name of Registrant as specified in its charter) IN DIANA 001-38661   82-5497352 (State or other jurisdiction of (Commission File   (I.R.S. Employer incorporation) Number)   Identification No.) 2500 INNOVATION WAY   46140 GREENFIELD , IN DIANA   (Zip Code) (Address of principal executive offices)   Registrant’s telephone number, including area code: ( 877 )  352-6261 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, no par value ELAN New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02    Results of Operations or Financial Condition. Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 26, 2024, announcing the results of operations for the full year and fiscal quarter ended December 31, 2023, and guidance for the full year and first quarter of 2024, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any regi

View on Read The Filing